UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Phase 2 Study of Allogeneic Mesenchymal Stromal Cells for Luminal Crohn's Disease Refractory to Biologic Therapy

Clinical gastroenterology and hepatology, 2014, Vol.12 (1), p.64-71

2014

Volltextzugriff (PDF)

Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection

Gastroenterology (New York, N.Y. 1943), 2016-07, Vol.151 (1), p.110-119

2016

Volltextzugriff (PDF)

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2017-07, Vol.390 (10090), p.135-144

2017

Volltextzugriff (PDF)

Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates

Alimentary pharmacology & therapeutics, 2021-04, Vol.53 (7), p.810-820

2021

Volltextzugriff (PDF)

Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions

Therapeutic Advances in Gastroenterology, 2018-01, Vol.11, p.1756284818772786-1756284818772786

2018

Volltextzugriff (PDF)

Predicting response after infliximab salvage in acute severe ulcerative colitis

Journal of gastroenterology and hepatology, 2018-07, Vol.33 (7), p.1347-1352

2018

Volltextzugriff (PDF)

Effect of Allopurinol on Clinical Outcomes in Inflammatory Bowel Disease Nonresponders to Azathioprine or 6-Mercaptopurine

Clinical gastroenterology and hepatology, 2007-02, Vol.5 (2), p.209-214

2007

Volltextzugriff (PDF)

The Role of Low-Dose Oral Methotrexate in Increasing Anti-TNF Drug Levels and Reducing Immunogenicity in IBD

Journal of clinical medicine, 2023-06, Vol.12 (13), p.4382

2023

Volltextzugriff (PDF)

A Personalized Approach to Managing Patients With an Ileal Pouch-Anal Anastomosis

Frontiers in medicine, 2020-01, Vol.6, p.337-337

2020

Volltextzugriff (PDF)

Quantification of Digestive Disease Damage in Crohn’s Disease, Are We There Yet With the Lémann Index?

Gastroenterology (New York, N.Y. 1943), 2021-09, Vol.161 (3), p.800-802

Sparrow, Miles P.

2021

Volltextzugriff (PDF)

Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study

Journal of Crohn's and colitis, 2018-02, Vol.12 (3), p.289-297

2018

Volltextzugriff (PDF)

B-Cell Dysregulation in Crohn's Disease Is Partially Restored with Infliximab Therapy

PloS one, 2016-07, Vol.11 (7), p.e0160103-e0160103

2016

Volltextzugriff (PDF)

Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease—Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics

Journal of clinical medicine, 2022-10, Vol.11 (20), p.6173

2022

Volltextzugriff (PDF)

Appropriateness of Testing for Anti–Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results

Clinical gastroenterology and hepatology, 2016-09, Vol.14 (9), p.1302-1309

2016

Volltextzugriff (PDF)

Editorial: is it not just PROs, but the most important individual PRO, that really matters in Crohn’s disease?

Alimentary pharmacology & therapeutics, 2022-04, Vol.55 (8), p.1038-1039

2022

Volltextzugriff (PDF)

A novel Monash Pouch diet in patients with an ileoanal pouch is tolerable and has favorable metabolic luminal effects

JGH open, 2023-12, Vol.7 (12), p.942-952

2023

Volltextzugriff (PDF)

Clinical utility of C‐reactive protein‐to‐albumin ratio in the management of patients with inflammatory bowel disease

JGH open, 2024-04, Vol.8 (4), p.e13059-n/a

2024

Volltextzugriff (PDF)

How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?

World journal of gastroenterology : WJG, 2015-10, Vol.21 (40), p.11331-11342

2015

Volltextzugriff (PDF)

Editorial: anti‐drug antibodies and the benefit of assay validation

Alimentary pharmacology & therapeutics, 2021-01, Vol.53 (1), p.194-195

2021

Volltextzugriff (PDF)

Adalimumab in ulcerative colitis - efficacy, safety and optimization in the era of treat-to target

Expert opinion on biological therapy, 2017-05, Vol.17 (5), p.613-621

Sparrow, Miles P.

2017

Volltextzugriff (PDF)

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases

Clinical gastroenterology and hepatology, 2019-08, Vol.17 (9), p.1655-1668.e3

2019

Volltextzugriff (PDF)

Thiopurines and risk of lymphoproliferative disorders

Australian prescriber, 2024-06, Vol.47 (3), p.91-93

2024

Volltextzugriff (PDF)

Can Subcutaneous Infliximab Replace Dose-Intensified Intravenous Administration in Inflammatory Bowel Disease?

Clinical gastroenterology and hepatology, 2023-08, Vol.21 (9), p.2430-2431

2023

Volltextzugriff (PDF)

Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2020-03, Vol.51 (6), p.612-628

2020

Volltextzugriff (PDF)

Infections in inflammatory bowel disease patients on immunomodulator and biologic therapy are not associated with high serum drug levels

Internal medicine journal, 2024-01, Vol.54 (1), p.139-148

2024

Volltextzugriff (PDF)

1 – 25 von 121

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(112)
Mit Volltextzugriff
(102)

Publikationsform

Sprache

Englisch
(120)
Japanisch
(11)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(90)
Life Sciences & Biomedicine
(89)
Gastroenterology & Hepatology
(68)
Humans
(64)
Inflammatory Bowel Disease
(48)
Ulcerative Colitis
(29)
Inflammatory Bowel Diseases - Drug Therapy
(28)
Female
(27)
Crohn's Disease
(25)
Adult
(21)
Infliximab
(20)
Male
(20)
Inflammatory Bowel Diseases
(17)
Treatment Outcome
(17)
Monoclonal Antibodies
(16)
Azathioprine
(15)
Middle Aged
(15)
Crohn Disease - Drug Therapy
(14)
Pharmacology & Pharmacy
(14)
Immunosuppressive Agents - Therapeutic Use
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

A Phase 2 Study of Allogeneic Mesenchymal Stromal Cells for Luminal Crohn's Disease Refractory to Biologic Therapy

Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates

Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions

Predicting response after infliximab salvage in acute severe ulcerative colitis

Effect of Allopurinol on Clinical Outcomes in Inflammatory Bowel Disease Nonresponders to Azathioprine or 6-Mercaptopurine

The Role of Low-Dose Oral Methotrexate in Increasing Anti-TNF Drug Levels and Reducing Immunogenicity in IBD

A Personalized Approach to Managing Patients With an Ileal Pouch-Anal Anastomosis

Quantification of Digestive Disease Damage in Crohn’s Disease, Are We There Yet With the Lémann Index?

Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study

B-Cell Dysregulation in Crohn's Disease Is Partially Restored with Infliximab Therapy

Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease—Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics

Appropriateness of Testing for Anti–Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results

Editorial: is it not just PROs, but the most important individual PRO, that really matters in Crohn’s disease?

A novel Monash Pouch diet in patients with an ileoanal pouch is tolerable and has favorable metabolic luminal effects

Clinical utility of C‐reactive protein‐to‐albumin ratio in the management of patients with inflammatory bowel disease

How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?

Editorial: anti‐drug antibodies and the benefit of assay validation

Adalimumab in ulcerative colitis - efficacy, safety and optimization in the era of treat-to target

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases

Thiopurines and risk of lymphoproliferative disorders

Can Subcutaneous Infliximab Replace Dose-Intensified Intravenous Administration in Inflammatory Bowel Disease?

Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease

Infections in inflammatory bowel disease patients on immunomodulator and biologic therapy are not associated with high serum drug levels

Suchergebnisse filtern